Anixa Biosciences, Inc. ANIX
Set alert
At close
Pre-market · Nov 2, 4:06 AM ET
- YTD
- 0.00%
- 1 year
- -23.15%
- Open
- 3.28
- Prev close
- 3.30
- Mkt cap
- 108.46M
- Vol
- 140.66K
- Avg vol
- 278.49K
- EPS
- -0.32
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.10
- High
- 3.35
- Forward P/E
- -7.17
- Beta
- 0.85
- Short ratio
- 3.03
- Inst. own
- 17.46%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Jan 21, 2025
- 50-d avg
- 3.17
- 200-d avg
- 3.04
- 1y target
- 8.50
News
6 days ago defenseworld.net
Anixa Biosciences (NASDAQ:ANIX) Share Price Breaks Below 200-Day Moving Average – Time to Sell?
Anixa Biosciences Inc (NASDAQ: ANIX - Get Free Report) shares crossed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $2.97 and traded as low as…
-
6 days ago benzinga.com
Anixa Biosciences Completes Dosing Of Fifth Group In Its Phase 1 Clinical Study Of FSHR-Targeted CAR-T Therapy To Treat Ovarian Cancer
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has completed dosing of the fifth
6 days ago prnewswire.com
Anixa Biosciences Announces Completion of Treatment of Fifth Cohort in its Ovarian Cancer CAR-T Clinical Trial
First patient in fifth cohort exhibiting stable disease 90 days after treatment Multiple patients surviving more than one year, including one beyond two years, with no dose-limiting toxicities…
-
3 weeks ago benzinga.com
Anixa Biosciences Participant In Its Current Phase 1 Study Of FSHR-Targeted CAR-T Therapy For Recurrant Ovarian Cancer Demonstrates Stable Disease After 90 Days Of Treatment; Patient Was Treated In Fifth Dose Cohort
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that a patient in its ongoing Phase 1,